Trevi Therapeutics, Inc. (TRVI): Price and Financial Metrics


Trevi Therapeutics, Inc. (TRVI)

Today's Latest Price: $3.90 USD

0.11 (2.90%)

Updated Sep 25 3:59pm

Add TRVI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

TRVI Daily Price Range
TRVI 52-Week Price Range

TRVI Stock Price Chart Technical Analysis Charts


TRVI Price/Volume Stats

Current price $3.90 52-week high $8.50
Prev. close $3.79 52-week low $1.33
Day low $3.76 Volume 12,159
Day high $3.91 Avg. volume 83,117
50-day MA $4.48 Dividend yield N/A
200-day MA $4.21 Market Cap 71.14M

Trevi Therapeutics, Inc. (TRVI) Company Bio


Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.


TRVI Latest News Stream


Event/Time News Detail
Loading, please wait...

TRVI Latest Social Stream


Loading social stream, please wait...

View Full TRVI Social Stream

Latest TRVI News From Around the Web

Below are the latest news stories about Trevi Therapeutics Inc that investors may wish to consider to help them evaluate TRVI as an investment opportunity.

Trevi Therapeutics to Present at H.C. Wainwright Global Investment Conference

NEW HAVEN, Conn., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will present a Company overview, as well as host virtual investor meetings, at the 2020 H.C. Wainwright Global Investment Conference on September 16, 2020: Presentation Time: 3:00 p.m. ETA live webcast of the presentation can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.The Company’s c...

Yahoo | September 9, 2020

Trevi Therapeutics, Inc. (TRVI) CEO Jennifer Good on Q2 2020 Results - Earnings Call Transcript

Trevi Therapeutics, Inc. (TRVI) Q2 2020 Earnings Conference Call August 13, 2020 04:30 PM ET Company Participants Jennifer Good - President and CEO Chris Seiter - CFO Conference Call Participants Gary Nachman - BMO Capital Ami Fabia - SVB Leerink Annabel Sami - Stifel Serge Belanger - Needham & Co...

SA Transcripts on Seeking Alpha | August 14, 2020

The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Allovir Inc (NASDAQ: ALVR ) Erytech Pharma SA (NASDAQ: ERYP ) Eyenovia Inc (NASDAQ: EYEN ) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) Evoke Pharma Inc (NASDAQ: EVOK ) Fortress Biotech (NASDAQ: FBIO )(reacted to its second-quarter results) GENMAB A/S/S ADR (NASDAQ: GMAB ) Inari Medical Inc (NASDAQ: NARI ) iTeos Therapeutics Inc (NASDAQ: ITOS ) Kura Oncology Inc (NASDAQ: KURA ) OncoSec Medical Inc (NASDAQ: ONCS ) Orthopediatrics Corp (NASDAQ: KIDS ) Pacira Biosciences Inc (NASDAQ: PCRX ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Silk Road Medical Inc (NASDAQ: SILK ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Down In The Dumps (Biotech Stocks Hittin...

Benzinga | August 12, 2020

Trevi Therapeutics to Report Q2 2020 Financial Results on August 13

Conference Call and Webcast to be Held at 4:30 p.m. ETNEW HAVEN, Conn., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast at 4:30 p.m. ET on August 13, 2020, to provide a corporate update and review the Company’s financial results for the second quarter ended June 30, 2020. To participate in the live conference call by phone, please dial 866-360-5746 (domestic) or 270-833-1418 (international) and provide access code 8162375. A live audio webcast will be accessible from the ‘Investors & News’ section on the Com...

Yahoo | August 6, 2020

Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference

NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that management will participate in a virtual fireside chat, as well as host virtual investor meetings, at the 2020 BTIG Biotechnology Conference on August 10, 2020: Presentation Time: 11:00 a.m. ETA live webcast of the virtual fireside chat can be accessed by visiting ‘News & Events’ in the ‘Investors & News’ section on the Company's website at www.trevitherapeutics.com. An archived replay of the webcast will also be available for 30 days on the Company's website following the conference.The Company’...

Yahoo | August 5, 2020

Read More 'TRVI' Stories Here

TRVI Price Returns

1-mo -0.51%
3-mo -35.54%
6-mo 128.07%
1-year -15.03%
3-year N/A
5-year N/A
YTD 4.00%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6371 seconds.